The DOI matches its Crossref record.
Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase–1
Abstract
Effective therapies for the treatment of obesity, a key element of metabolic syndrome, are urgently needed but currently lacking. Stearoyl-CoA desaturase–1 (SCD1) is the rate-limiting enzyme catalyzing the conversion of saturated long-chain fatty acids into monounsaturated fatty acids, which are major components of triglycerides. In the current study, we tested the efficacy of pharmacological inhibition of SCD1 in controlling lipogenesis and body weight in mice. SCD1-specific antisense oligonucleotide inhibitors (ASOs) reduced SCD1 expression, reduced fatty acid synthesis and secretion, and increased fatty acid oxidization in primary mouse hepatocytes. Treatment of mice with SCD1 ASOs resulted in prevention of diet-induced obesity with concomitant reductions in SCD1 expression and the ratio of oleate to stearoyl-CoA in tissues and plasma. These changes correlated with reduced body adiposity, hepatomegaly and steatosis, and postprandial plasma insulin and glucose levels. Furthermore, SCD1 ASOs reduced de novo fatty acid synthesis, decreased expression of lipogenic genes, and increased expression of genes promoting energy expenditure in liver and adipose tissues. Thus, SCD1 inhibition represents a new target for the treatment of obesity and related metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 33
- Kopelman, 2000, Nature., 404, 635, 10.1038/35007508 · DOI · Paper page
- 10.1126/science.304.5676.1413 · DOI · Paper page
- Enoch, 1976, J. Biol. Chem., 251, 5095, 10.1016/S0021-9258(17)33223-4 · DOI · Paper page
- 10.1016/S0163-7827(03)00039-0 · DOI · Paper page
- 10.1006/geno.2000.6429 · DOI · Paper page
- 10.1074/jbc.M304724200 · DOI · Paper page
- 10.1042/0264-6021:3400255 · doi:10.1042/0264-6021:3400255 · Paper page
- 10.1016/S0378-1119(03)00461-X · doi:10.1016/s0378-1119(03)00461-x
- 10.1016/0163-7827(94)00010-J · DOI · Paper page
- Waters, 1994, J. Biol. Chem., 269, 27773, 10.1016/S0021-9258(18)47053-6 · DOI
- Ntambi, 1992, J. Biol. Chem., 267, 10925, 10.1016/S0021-9258(19)50107-7 · DOI · Paper page
- 10.2174/1568008033340117 · DOI
- 10.1016/j.tcm.2003.12.005 · DOI
- 10.1038/15446 · DOI · Paper page
- 10.1074/jbc.M005488200 · DOI · Paper page
- 10.1126/science.1071527 · DOI · Paper page
- 10.1073/pnas.132384699 · DOI · Paper page
- Asilmaz, 2004, J. Clin. Invest., 113, 414, 10.1172/JCI200419511 · DOI · Paper page
- 10.1073/pnas.0401627101 · DOI · Paper page
- 10.1194/jlr.M400039-JLR200 · DOI
- 10.1194/jlr.M200189-JLR200 · DOI · Paper page
- 10.1073/pnas.1934571100 · DOI · Paper page
- 10.1210/en.2004-0778 · DOI
- 10.1016/S0303-7207(03)00008-X · DOI
- Muse, 2004, J. Clin. Invest., 114, 232, 10.1172/JCI200421270 · DOI · Paper page
- 10.1074/jbc.272.18.11994 · DOI · Paper page
- Neufeld, 1997, Methods Mol. Biol., 75, 145
- McGarry, 1978, J. Biol. Chem., 253, 8294, 10.1016/S0021-9258(17)34395-8 · DOI · Paper page
- Kalopissis, 1981, Biochem. J., 198, 373, 10.1042/bj1980373 · doi:10.1042/bj1980373
- Mannaerts, 1979, J. Biol. Chem., 254, 4585, 10.1016/S0021-9258(17)30051-0 · DOI · Paper page
- 10.2337/diabetes.51.8.2412 · DOI
- Sakurai, 1974, Biochim. Biophys. Acta., 360, 275, 10.1016/0005-2760(74)90057-5 · DOI
- 10.1172/JCI103259 · DOI · Paper page
Cited by
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082
Self-citationPostic, C., & Girard, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34275 · Cited by 1,204
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease
Softic, S., Cohen, D. E., & Kahn, C. R. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4054-0 · Cited by 709
Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance
Matsuzaka, T., Shimano, H., Yahagi, N., Kato, T., Atsumi, A., Yamamoto, T., Inoue, N., Ishikawa, M., Okada, S., Ishigaki, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1662 · Cited by 542
Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism
Flowers, M. T., & Ntambi, J. M. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282f9b54d · Cited by 438
Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
Koo, S.-H. (2013) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2013.19.3.210 · Cited by 421
Genetic control of de novo lipogenesis: role in diet-induced obesity
Strable, M. S., & Ntambi, J. M. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409231003667500 · Cited by 416
Miyazaki, M., Flowers, M. T., Sampath, H., Chu, K., Otzelberger, C., Liu, X., & Ntambi, J. M. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.014 · Cited by 414
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Self-citationHepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease
Li, Z. Z., Berk, M., McIntyre, T. M., & Feldstein, A. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807616200 · Cited by 400
Self-citationEvolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
Peverill, W., Powell, L., & Skoien, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058591 · Cited by 376
Yu, X. X., Murray, S. F., Pandey, S. K., Booten, S. L., Bao, D., Song, X., Kelly, S., Chen, S., McKay, R., Monia, B. P., et al. (2005) · Hepatology · doi:10.1002/hep.20783 · Cited by 301
Gutierrez-Juarez, R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26991 · Cited by 296
The role of the lipogenic pathway in the development of hepatic steatosis
Postic, C., & Girard, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74599-3 · Cited by 288
ChREBP, a Transcriptional Regulator of Glucose and Lipid Metabolism
Postic, C., Dentin, R., Denechaud, P.-D., & Girard, J. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093618 · Cited by 283
Metabolic disturbances in non-alcoholic fatty liver disease
Byrne, C. D., Olufadi, R., Bruce, K. D., Cagampang, F. R., & Ahmed, M. H. (2009) · Clinical Science · doi:10.1042/cs20080253 · Cited by 258
Rizki, G., Arnaboldi, L., Gabrielli, B., Yan, J., Lee, G. S., Ng, R. K., Turner, S. M., Badger, T. M., Pitas, R. E., & Maher, J. J. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600198-jlr200 · Cited by 258
BAM15‐mediated mitochondrial uncoupling protects against obesity and improves glycemic control
Axelrod, C. L., King, W. T., Davuluri, G., Noland, R. C., Hall, J., Hull, M., Dantas, W. S., Zunica, E. R., Alexopoulos, S. J., Hoehn, K. L., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012088 · Cited by 89
Thermogenic and metabolic antiobesity drugs: rationale and opportunities
Clapham, J. C., & Arch, J. R. S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00608.x · Cited by 60
Yang, Z.-H., Miyahara, H., Mori, T., Doisaki, N., & Hatanaka, A. (2011) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf201496h · Cited by 49
Metadata
- Authors
- Jiang, G., Li, Z., Liu, F., Ellsworth, K., Dallas-Yang, Q., Wu, M., Ronan, J., Esau, C., Murphy, C., Szalkowski, D., Bergeron, R., Doebber, T., & Zhang, B. B.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-03-10
- Volume
- 115
- Issue
- 4
- Pages
- 1030-1038
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4237377343
- Cited by
- 241
- References
- 0
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.